https://orcid.org/0000-0001-9687-5677
References
- Petrara MR, Giunco S, Serraino D, et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett. 2015;369(1):37–44.
- Green M, Michaels MG. Epstein–Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(s3):41–54.
- Parker A, Bowles K, Bradley JA, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010;149(5):693–705.
- Bishnoi R, Bajwa R, Franke AJ, et al. Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol. 2017;6(1):26.
- Jagadeesh D, Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol. 2012;13(1):122–136.
- Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative disorder (★). Am J Transplant. 2011;11(2):336–347.
- Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076–1088.
- Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008;86(2):215–222.
- Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–183.
- Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–562.
- Li J, Liu Y, Wang Z, et al. Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts: a case report and literature review. Medicine (Baltimore). 2018;97(17):e0531.
- Rabot N, Büchler M, Foucher Y, et al. CNI withdrawal for post‐transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Transpl Int. 2014;27(9):956–965.
- Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038–1046.